AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20508383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) value of 102 mg/dL
Number of subjects: 2207
Study 20508383 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin A(1c) level > or = 6.1%
Number of subjects: 2207
Study 18353592 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hydroxy-anethole trithione (ATX) tablets produced by different companies
Number of subjects: 20
Study 18353592 — intervention group
Group type: COMPARATOR
Intervention: ATX tablets
Number of subjects: 20
Study 17117566 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus western medicine (treatment group)
Number of subjects: 26
Study 17117566 — intervention group
Group type: COMPARATOR
Intervention: Simple western medicine (control group)
Number of subjects: 26
Study 12842239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol treatment
Number of subjects: 30
Study 12842239 — intervention group
Group type: COMPARATOR
Intervention: Aspirin treatment
Number of subjects: 30
Study 12842239 — intervention group
Group type: COMPARATOR
Intervention: No antiplatelet agent treatment
Number of subjects: 30
Study 10923774 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 120
Study 10923774 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 120
Study 10923774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 24 mg
Number of subjects: 120
Study 10923774 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 120
Study 8831519 — intervention group
Group type: EXPERIMENTAL
Intervention: Single staple technique
Number of subjects: 0
Study 8831519 — intervention group
Group type: COMPARATOR
Intervention: Double staple technique
Number of subjects: 0
Study 8831519 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically detected dehiscence
Number of subjects: 0
Study 8831519 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologically detected dehiscence
Number of subjects: 0
Study 1335199 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable interrupted sutures (Dexon 6x0)
Number of subjects: 100
Study 1335199 — intervention group
Group type: COMPARATOR
Intervention: Adhesive plasters (Leukostrip)
Number of subjects: 100
Study 4032389 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavage with 800 ml of saline plus 2 gm of cefamandole nafate
Number of subjects: 0
Study 4032389 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavage with 800 ml of saline alone
Number of subjects: 0
Study 4032389 — intervention group
Group type: COMPARATOR
Intervention: No lavage
Number of subjects: 0
Study 31238975 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus cisplatin and chemoradiotherapy
Number of subjects: 480
Study 31238975 — intervention group
Group type: COMPARATOR
Intervention: chemoradiotherapy alone
Number of subjects: 480
Study 29977280 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation Training (AOT)
Number of subjects: 64
Study 29977280 — intervention group
Group type: COMPARATOR
Intervention: Control group (landscape-videos observation)
Number of subjects: 64
Study 27787363 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 5 μg/kg immediately before propofol administration
Number of subjects: 173
Study 27787363 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 2.5 μg/kg immediately before propofol administration
Number of subjects: 173
Study 27787363 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 5 μg/kg 2 minutes before propofol administration
Number of subjects: 173
Study 27787363 — intervention group
Group type: COMPARATOR
Intervention: Propofol administration alone (control group 5)
Number of subjects: 173
Study 24867835 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox treatment
Number of subjects: 688
Study 24867835 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 688
Study 22677437 — intervention group
Group type: EXPERIMENTAL
Intervention: Online group course (Grip op Je Dip / Master Your Mood)
Number of subjects: 244
Study 22677437 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 244
Study 20187097 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 540
Study 20187097 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model based on multiple linear regressions
Number of subjects: 540
Study 18599126 — intervention group
Group type: EXPERIMENTAL
Intervention: Client version of the Illness Management and Recovery (IMR) scale
Number of subjects: 210
Study 18599126 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician version of the Illness Management and Recovery (IMR) scale
Number of subjects: 210
Study 18599126 — intervention group
Group type: EXPERIMENTAL
Intervention: Client responses to the client IMR scale
Number of subjects: 210
Study 18599126 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician responses to the clinician IMR scale
Number of subjects: 210
Study 18599126 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping efficacy and social support measures (reported by clients)
Number of subjects: 210
Study 19637997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite (NHA)
Number of subjects: 20
Study 19637997 — intervention group
Group type: COMPARATOR
Intervention: Natural bone mineral in combination with a collagen membrane (NBM+CM)
Number of subjects: 20
Study 15167475 — intervention group
Group type: EXPERIMENTAL
Intervention: Schilder's warm vertical condensation
Number of subjects: 4
Study 15167475 — intervention group
Group type: EXPERIMENTAL
Intervention: Schilder's technique modified by using an electric heater
Number of subjects: 4
Study 15167475 — intervention group
Group type: EXPERIMENTAL
Intervention: Schilder's technique modified by compaction of the apical tract at body temperature
Number of subjects: 4
Study 15167475 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified vertical compaction with apical back‐filling
Number of subjects: 4
Study 11318057 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice
Number of subjects: 0
Study 11318057 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice
Number of subjects: 0
Study 9159678 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mm temporal clear corneal incision
Number of subjects: 80
Study 9159678 — intervention group
Group type: COMPARATOR
Intervention: 3.0 mm superior scleral tunnel incision
Number of subjects: 80
Study 8253560 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam or clindamycin
Number of subjects: 43
Study 3521842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) 5-Fluorouracil (5-FU) chemotherapy
Number of subjects: 0
Study 3521842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) 5-Fluorouracil (5-FU) chemotherapy
Number of subjects: 0
Study 3521842 — intervention group
Group type: COMPARATOR
Intervention: Pelvic radiation therapy
Number of subjects: 0
Study 3521842 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU) chemotherapy (both IP and IV)
Number of subjects: 0
Study 11762429 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus control/sleep restriction
Number of subjects: 90
Study 11762429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Number of subjects: 90
Study 11762429 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 90
Study 11762429 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene
Number of subjects: 90
Study 11762429 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery training
Number of subjects: 90
Study 30934886 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 0
Study 30934886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30399108 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women (BMI ≥30)
Number of subjects: 948
Study 30399108 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight women (BMI 25.0-29.9)
Number of subjects: 948
Study 30399108 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight women (BMI 18.5-24.9)
Number of subjects: 948
Study 30399108 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate gestational weight gain
Number of subjects: 948
Study 30399108 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate gestational weight gain
Number of subjects: 948
Study 30399108 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive gestational weight gain
Number of subjects: 948
Study 27526497 — intervention group
Group type: EXPERIMENTAL
Intervention: Areas designated as nonattainment for PM10
Number of subjects: 4000000
Study 27526497 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of SO2 scrubber on coal-fired power plants
Number of subjects: 4000000
Study 24571754 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Number of subjects: 10007
Study 24571754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10007
Study 22240036 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 126
Study 22240036 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients with BDI score≥17
Number of subjects: 126
Study 22240036 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 126
Study 20233669 — intervention group
Group type: EXPERIMENTAL
Intervention: ReNu MultiPlus Multipurpose Solution with PureVision silicon hydrogel contact lens
Number of subjects: 25
Study 18519845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (angiotensin-converting enzyme blocker)
Number of subjects: 28
Study 18519845 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (beta-blocker)
Number of subjects: 28
Study 18519845 — intervention group
Group type: COMPARATOR
Intervention: Both medications (Lisinopril and Atenolol)
Number of subjects: 28
Study 15811868 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA (balloon angioplasty)
Number of subjects: 2082
Study 15811868 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 2082
Study 15811868 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting + abciximab
Number of subjects: 2082
Study 12499819 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemo‐radiation therapy (external beam radiotherapy 4,500 cGy over 5 weeks and intrahepatic arterial 5‐FU infusion 500 mg on days 1-5 and 30-35)
Number of subjects: 54
Study 12499819 — intervention group
Group type: COMPARATOR
Intervention: Intrahepatic arterial cisplatin infusion (80 mg/m(2))
Number of subjects: 54
Study 10417455 — intervention group
Group type: EXPERIMENTAL
Intervention: 25G Whitacre spinal needle
Number of subjects: 130
Study 10417455 — intervention group
Group type: EXPERIMENTAL
Intervention: 25G Quincke spinal needle
Number of subjects: 130
Study 10417455 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraesthesia occurrence
Number of subjects: 130
Study 10417455 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of needle passes
Number of subjects: 130
Study 10417455 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet drug therapy
Number of subjects: 130
Study 10417455 — intervention group
Group type: COMPARATOR
Intervention: Spinal needle type
Number of subjects: 130
Study 7739736 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib vaccine (administered at 3, 4, 5, and 11 months)
Number of subjects: 21
Study 7739736 — intervention group
Group type: COMPARATOR
Intervention: Control group (children born from April 1, 1991 to April 1, 1993 who were not vaccinated)
Number of subjects: 21
Study 1971472 — intervention group
Group type: EXPERIMENTAL
Intervention: Medetomidine (50 micrograms)
Number of subjects: 10
Study 1971472 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study 6996929 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g magnesium dithiosalicylate daily
Number of subjects: 40
Study 6996929 — intervention group
Group type: COMPARATOR
Intervention: 3 g aspirin daily
Number of subjects: 40
Study 31409302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 246
Study 29089356 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (40 mg orally, twice daily) for 2 months
Number of subjects: 30
Study 29089356 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 30
Study 29089356 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 30
Study 26699125 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIST nomination process
Number of subjects: 0
Study 26699125 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 0
Study 26699125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools
Number of subjects: 0
Study 26699125 — intervention group
Group type: EXPERIMENTAL
Intervention: Three simple questions for identification
Number of subjects: 0
Study 25040433 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based interactive distraction (TBID)
Number of subjects: 108
Study 25040433 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.5 mg·kg(‐1); 20 mg max)
Number of subjects: 108
Study 21678167 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW) about body concerns
Number of subjects: 111
Study 21678167 — intervention group
Group type: COMPARATOR
Intervention: Control writing condition
Number of subjects: 111
Study 20737167 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (intervention group)
Number of subjects: 16
Study 20737167 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral and supinated positions (intervention group)
Number of subjects: 16
Study 20737167 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position (intervention group)
Number of subjects: 16
Study 20737167 — intervention group
Group type: EXPERIMENTAL
Intervention: All forearm positions (intervention group)
Number of subjects: 16
Study 19219086 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled in the program
Number of subjects: 11610
Study 19219086 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11610
Study 15982127 — intervention group
Group type: EXPERIMENTAL
Intervention: Global optic flow rate manipulation
Number of subjects: 0
Study 15982127 — intervention group
Group type: EXPERIMENTAL
Intervention: Edge rate manipulation
Number of subjects: 0
Study 15982127 — intervention group
Group type: EXPERIMENTAL
Intervention: Global optic flow rate
Number of subjects: 0
Study 12605342 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin treatment
Number of subjects: 0
Study 12605342 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight persons
Number of subjects: 0
Study 11136260 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled triamcinolone acetonide 600 microg twice daily
Number of subjects: 1116
Study 11136260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1116
Study 8817984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nikkiso centrifugal pump during CPB
Number of subjects: 23
Study 1449922 — intervention group
Group type: EXPERIMENTAL
Intervention: +/- Candoxatrilat
Number of subjects: 6
Study 1449922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6208231 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine-adsorbed Dpt extract
Number of subjects: 18
Study 6208231 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 18
Study 31386180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 0
Study 31386180 — intervention group
Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 0
Study 29735484 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 200 mg single dose
Number of subjects: 501
Study 29735484 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg 2-dose regimen (100 mg on day 1 and 300 mg on day 90)
Number of subjects: 501
Study 29735484 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg 2-dose regimen
Number of subjects: 501
Study 26932420 — intervention group
Group type: EXPERIMENTAL
Intervention: High temporal structure attorney questioning
Number of subjects: 0
Study 26932420 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct examination
Number of subjects: 0
Study 26932420 — intervention group
Group type: COMPARATOR
Intervention: Low temporal structure attorney questioning
Number of subjects: 0
Study 26932420 — intervention group
Group type: COMPARATOR
Intervention: Cross-examination
Number of subjects: 0
Study 24591266 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 26
Study 24591266 — intervention group
Group type: COMPARATOR
Intervention: Melatonin
Number of subjects: 26
Study 23044303 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (n = 41)
Number of subjects: 81
Study 23044303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (n = 40)
Number of subjects: 81
Study 23044303 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant treatment using lipoic acid
Number of subjects: 81
Study 23044303 — intervention group
Group type: COMPARATOR
Intervention: Normal Control Group (NC group, n = 79)
Number of subjects: 81
Study 20492627 — intervention group
Group type: EXPERIMENTAL
Intervention: Shampoo treatment with ultrapure soft water (UPSW)
Number of subjects: 11
Study 20492627 — intervention group
Group type: COMPARATOR
Intervention: Shampoo treatment with tap water
Number of subjects: 11
Study 18579755 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Addition Lenses (PALs) with near addition of +1.50 D for 18 months
Number of subjects: 92
Study 18579755 — intervention group
Group type: COMPARATOR
Intervention: Single-Vision Lenses (SVLs) for 18 months
Number of subjects: 92
Study 16075658 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 121
Study 16075658 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (20-50 mg/day)
Number of subjects: 121
Study 16075658 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 121
Study 16075658 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 121
Study 11921320 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus hormonal therapy
Number of subjects: 0
Study 11921320 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy
Number of subjects: 0
Study 9696733 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine, 30 mg/d for 15 weeks
Number of subjects: 176
Study 9156956 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once daily)
Number of subjects: 226
Study 9156956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during the 4-week withdrawal phase)
Number of subjects: 226
Study 9156956 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 226
Study 2649379 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of non-Hodgkin's lymphomas (NHL) among patients originally diagnosed as HD.
Number of subjects: 312
Study 2649379 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of Hodgkin's disease (HD)
Number of subjects: 312
Study 1115011 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg of pyridoxine hydrochloride
Number of subjects: 24
Study 1115011 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg of pyridoxine hydrochloride
Number of subjects: 24
Study 1115011 — intervention group
Group type: EXPERIMENTAL
Intervention: 20.0 mg of pyridoxine hydrochloride
Number of subjects: 24
Study 1115011 — intervention group
Group type: COMPARATOR
Intervention: Diet deficient in vitamin B6
Number of subjects: 24
Study 31805778 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 37
Study 31805778 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 37
Study 29535340 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal HD-tDCS
Number of subjects: 45
Study 29535340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal HD-tDCS
Number of subjects: 45
Study 29535340 — intervention group
Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 45
Study 26847922 — intervention group
Group type: EXPERIMENTAL
Intervention: Low unsaturated long-chain phosphatidylcholines and lysophosphatidylcholines species
Number of subjects: 20
Study 26847922 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating kynurenine
Number of subjects: 20
Study 26847922 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease of glycerophospholipids
Number of subjects: 20
Study 26847922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular SOFA score
Number of subjects: 20
Study 26847922 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy
Number of subjects: 20
Study 24971340 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat
Number of subjects: 7
Study 24971340 — intervention group
Group type: COMPARATOR
Intervention: Manual Treadmill
Number of subjects: 7
Study 24971340 — intervention group
Group type: COMPARATOR
Intervention: ZeroG
Number of subjects: 7
Study 24971340 — intervention group
Group type: COMPARATOR
Intervention: Manual Treadmill and ZeroG
Number of subjects: 7
Study 22404731 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus divalproate
Number of subjects: 41
Study 22404731 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol plus divalproate
Number of subjects: 41
Study 20176498 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GH group (0.012 mg/kg/day)
Number of subjects: 96
Study 20176498 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose GH group (0.006 mg/kg/day)
Number of subjects: 96
Study 20176498 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 96
Study 18803944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral D-chiro-inositol (DCI) supplementation
Number of subjects: 11
Study 18803944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15695748 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator group
Number of subjects: 60
Study 15695748 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 15695748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain group
Number of subjects: 60
Study 12368782 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion for 48 hours
Number of subjects: 26